Trotta Matteo 4

What Happened Matteo Trotta, EVP & GM, Dermatology US at Incyte Corporation, received a grant of 8,542 derivative shares on January 16, 2026. The filing reports an acquisition at $0.00 per share (total reported value $0), indicating a compensation award rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-01-16; Form 4 filed: 2026-01-21.
• Quantity: 8,542 derivative shares acquired at $0.00 (reported value $0).
• Shares owned after the transaction: not specified in the filing.
• Footnote: options become exercisable in 37 installments — first 25% vests on July 15, 2026; the remainder vests monthly over three years.
• Transaction type: Award/Grant (code A); this is a compensation grant, not an immediate market purchase or sale.

Context This is a company compensation award (derivative securities). For retail investors, grants signal management compensation alignment with company performance but are not the same as an insider buying shares with personal funds. The footnote indicates these awards have a multi-year exercisability/vesting schedule, so any potential ownership impact will accrue over time.